

# Marco Tagliamento

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1178177/publications.pdf>

Version: 2024-02-01

73  
papers

1,648  
citations

279701

23  
h-index

330025

37  
g-index

74  
all docs

74  
docs citations

74  
times ranked

2791  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. <i>European Journal of Cancer</i> , 2020, 139, 43-50.	1.3	267
2	The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. <i>Journal of Translational Medicine</i> , 2019, 17, 74.	1.8	103
3	Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2022, 160, 243-260.	1.3	93
4	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680.	5.1	73
5	Radiomic Detection of EGFR Mutations in NSCLC. <i>Cancer Research</i> , 2021, 81, 724-731.	0.4	57
6	Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 125.	2.2	53
7	Time-Dependent COVID-19 Mortality in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 114.	3.4	50
8	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. <i>Lancet Oncology</i> , The, 2022, 23, 865-875.	5.1	50
9	Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. <i>ESMO Open</i> , 2018, 3, e000361.	2.0	49
10	Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103365.	2.0	48
11	Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1011.	1.0	45
12	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. <i>Cancers</i> , 2020, 12, 1125.	1.7	43
13	Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities. <i>JCO Oncology Practice</i> , 2020, 16, e1304-e1314.	1.4	38
14	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , 2021, 7, 162-172.	0.8	38
15	Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2625.	1.8	38
16	Update on the Management of Breast Cancer during Pregnancy. <i>Cancers</i> , 2020, 12, 3616.	1.7	37
17	Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. <i>European Journal of Cancer</i> , 2022, 167, 142-148.	1.3	32
18	Call for ensuring cancer care continuity during COVID-19 pandemic. <i>ESMO Open</i> , 2020, 5, e000783.	2.0	31

#	ARTICLE	IF	CITATIONS
19	VISTA: A Promising Target for Cancer Immunotherapy?. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 185-200.	2.7	31
20	Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , 2020, 5, e000853.	2.0	29
21	Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13315.	1.7	28
22	Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 2055-2062.	0.9	27
23	Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1566.	1.0	26
24	The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1969-1976.	0.9	24
25	Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1351-1358.	2.0	24
26	New emerging targets in cancer immunotherapy: the role of VISTA. <i>ESMO Open</i> , 2019, 4, e000683.	2.0	24
27	Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 269-275.	1.1	24
28	Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 573-585.	1.0	21
29	Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 513-523.	1.9	21
30	Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 367-383.	1.0	21
31	CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 829-835.	1.4	17
32	The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. <i>Cancers</i> , 2021, 13, 3117.	1.7	17
33	The use of immunotherapy in older patients with advanced non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2022, 106, 102394.	3.4	16
34	Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer. <i>Clinical and Experimental Metastasis</i> , 2019, 36, 449-456.	1.7	15
35	Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients. <i>Breast Cancer: Basic and Clinical Research</i> , 2020, 14, 117822342095417.	0.6	15
36	Emerging issues related to COVID-19 vaccination in patients with cancer. <i>Oncology and Therapy</i> , 2021, , 1-11.	1.0	15

#	ARTICLE	IF	CITATIONS
37	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 979-987.	3.0	14
38	A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103639.	2.0	13
39	Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. <i>Immunotherapy</i> , 2019, 11, 873-879.	1.0	12
40	Performance of the OncoPrint™ Lung cfDNA Assay for Liquid Biopsy by NGS of NSCLC Patients in Routine Laboratory Practice. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2895.	1.3	7
41	Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492093181.	0.6	7
42	Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer. <i>JCO Global Oncology</i> , 2022, 8, e2100153.	0.8	6
43	Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 551-561.	1.9	5
44	Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13668.	1.7	5
45	Denosumab related osteonecrosis of the jaw: Unusual pattern with periosteal reaction. <i>European Journal of Cancer</i> , 2022, 166, 33-37.	1.3	5
46	A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 3412.	1.7	4
47	ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 679-686.	0.9	3
48	Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment. <i>Clinical and Translational Oncology</i> , 2020, 22, 1603-1610.	1.2	3
49	Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations. <i>Immunotherapy</i> , 2021, 13, 509-525.	1.0	3
50	Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 341-351.	1.0	3
51	Heterogeneity of treatment effects in malignant pleural mesothelioma. <i>Lancet, The</i> , 2021, 398, 301-302.	6.3	3
52	Overall survival (OS) of selected patients (Pts) with non-small cell lung cancer (NSCLC) receiving nivolumab beyond progression. <i>Annals of Oncology</i> , 2017, 28, vi61.	0.6	2
53	P2.14-02 Interim Survival Analysis of Gefitinib Plus Vinorelbine in Advanced EGFR-Mutant Non-Small Cell Lung Cancer (Genoa Trial). <i>Journal of Thoracic Oncology</i> , 2019, 14, S829-S830.	0.5	2
54	1277P An exosomal miRNA signature as predictor of benefit from immune checkpoint inhibitors in non-small cell lung cancer. <i>Annals of Oncology</i> , 2020, 31, S825-S826.	0.6	2

#	ARTICLE	IF	CITATIONS
55	1740P Assessing the impact of COVID-19 outbreak on the attitudes and practice of Italian oncologists towards breast cancer care and related research activities. <i>Annals of Oncology</i> , 2020, 31, S1017.	0.6	1
56	PARP inhibitors (PARPi) for the treatment of <i>BRCA</i> -mutated HER2-negative (HER2-) metastatic breast cancer (MBC) patients: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13098-e13098.	0.8	1
57	18F-FDG PET-derived parameter total lesion glycolysis (TLG) as a tool to stratify patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9062-9062.	0.8	1
58	P1.04-15 Computerized Tomography Texture Analysis as Biomarker of Benefit from Nivolumab in Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, S531.	0.5	0
59	P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab. <i>Journal of Thoracic Oncology</i> , 2018, 13, S730-S731.	0.5	0
60	P2.03-28 Whole Exome Sequencing to Discover Lung Tumor Predisposition in Women with Previous Breast Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, S726-S727.	0.5	0
61	Lung cancer predisposition in women with previous breast cancer identified by whole exome sequencing. <i>Annals of Oncology</i> , 2018, 29, viii674.	0.6	0
62	A systematic review and meta-analysis of trials assessing activity of PD-1/PD-L1 immune checkpoint inhibitors (ICIs) for pre-treated advanced malignant mesothelioma (aMM). <i>Annals of Oncology</i> , 2019, 30, xi28.	0.6	0
63	P2.01-74 Clinical-Pathological Features and Outcome of Patients with Oral Metastases from Lung Cancer: A Multicenter Retrospective Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, S668-S669.	0.5	0
64	P2.14-17 Correlation Between Clinic-Pathological Data and T790M Detection in EGFR Mutated NSCLC Patients Progressing on 1st/2nd Generation TKIs. <i>Journal of Thoracic Oncology</i> , 2019, 14, S835-S836.	0.5	0
65	1216P A circulating exosomal miRNA-based risk score as a predictive biomarker of relapse in early stage non-small cell lung cancer. <i>Annals of Oncology</i> , 2020, 31, S795.	0.6	0
66	1318P Association between soluble PD-L1 and prognosis of non-small cell lung cancer (NSCLC) patients treated with immunotherapy. <i>Annals of Oncology</i> , 2020, 31, S851.	0.6	0
67	1700P Perception and attitudes of Italian physicians towards the management of checkpoint inhibitors in oncology during COVID-19 outbreak: Results from a national survey. <i>Annals of Oncology</i> , 2020, 31, S1002-S1003.	0.6	0
68	Mortality in adult patients with solid or hematological cancers and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18608-e18608.	0.8	0
69	Safety of using hormone replacement therapy in breast cancer survivors: A systematic review and metanalysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12067-12067.	0.8	0
70	Cancer pathways analysis and correlation with survival in patients with advanced stage non-small cell lung cancer treated with PD-1 inhibitor.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21007-e21007.	0.8	0
71	Estimating Mortality in Patients with Hematological Malignancy and COVID-19: A Pooled Analysis of 10 Studies. <i>Blood</i> , 2020, 136, 13-14.	0.6	0
72	Comment on "Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis". <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0

#	ARTICLE	IF	CITATIONS
73	The FLARE score, circulating neutrophils, and association with COVID-19 outcomes in patients with solid tumors.. Journal of Clinical Oncology, 2022, 40, 2551-2551.	0.8	0